14423-00-8Relevant articles and documents
The 1,4-naphthoquinone scaffold in the design of cysteine protease inhibitors
Valente, Claudia,Moreira, Rui,Guedes, Rita C.,Iley, Jim,Jaffar, Mohammed,Douglas, Kenneth T.
, p. 5340 - 5350 (2007)
A series of 1,4-naphthoquinone derivatives diversely substituted at C-2, C-3, C-5 and C-8, prepared by reaction of amines, amino acids and alcohols with commercial 1,4-naphthoquinones, has been evaluated against papain and bovine spleen cathepsin B. These
-
Fieser,Fieser
, p. 491 (1935)
-
Method for synthesizing 2-substituted amino-1,4-naphthoquinone derivative
-
Paragraph 0122-0127, (2019/05/28)
The invention discloses a method for synthesizing a 2-substituted amino-1,4-naphthoquinone derivative. The method comprises the following steps: mixing a nitro compound, 2-substituted 1,4-naphthoquinone, a catalyst, a metal and a solvent uniformly at 20-100 DEG C; adding an H source, stirring the components for reaction for 1-24h; performing a reduction-addition reaction between the nitro compoundand the 2-substituted 1,4-naphthoquinone; after the reaction, adding water to the reaction system for dilution; performing filtering; extracting filtrate with ethyl acetate; after organic phases arecombined, washing the mixture with saturated saline solution and drying the mixture with anhydrous sodium sulfate sequentially; subsequently, performing filtering, and performing vacuum concentrationto remove a solvent; and packing solids into a column, and performing separation through column chromatography (a ratio of petroleum ether to ethyl acetate is 5:1) to obtain red solids. Compared withan existing synthesis method, the synthesis method provided by the invention has a wide range of raw materials and the raw materials are easy to obtain; compared with amine compounds, nitro compoundshave better stability; and the synthesis method provided by the invention is simple to operate and mild in reaction condition.
INHIBITORS OF THE MITF MOLECULAR PATHWAY
-
Paragraph 00348, (2015/01/09)
Provided herein are compounds of the formula (IV) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful as MITF inhibitors, MITF pathway inhibitors and for the treatment of cancer.